Evidence map›Paper›PMID 41422301›Full record

ArticleGut pathogens2025

The microbiological and clinical characteristics of 1,204 human cases of Aliarcobacter spp. infections that occurred in France between 2002 and 2024.

Marine Jauvain, Lucie Bruhl, Astrid Ducournau, Johanna Aptel, Moeava Martin, Philippe Lehours

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marine JauvainLaboratoire de Bactériologie, CHU de Bordeaux, CHU Pellegrin, CNR des Campylobacters et des Hélicobacters, Place Amélie Raba Léon, Bordeaux, Cedex 33076, France.
Lucie BruhlLaboratoire de Bactériologie, CHU de Bordeaux, CHU Pellegrin, CNR des Campylobacters et des Hélicobacters, Place Amélie Raba Léon, Bordeaux, Cedex 33076, France.
Astrid DucournauLaboratoire de Bactériologie, CHU de Bordeaux, CHU Pellegrin, CNR des Campylobacters et des Hélicobacters, Place Amélie Raba Léon, Bordeaux, Cedex 33076, France.
Johanna AptelLaboratoire de Bactériologie, CHU de Bordeaux, CHU Pellegrin, CNR des Campylobacters et des Hélicobacters, Place Amélie Raba Léon, Bordeaux, Cedex 33076, France.
Moeava MartinLaboratoire de Bactériologie, CHU de Bordeaux, CHU Pellegrin, CNR des Campylobacters et des Hélicobacters, Place Amélie Raba Léon, Bordeaux, Cedex 33076, France.
Philippe LehoursLaboratoire de Bactériologie, CHU de Bordeaux, CHU Pellegrin, CNR des Campylobacters et des Hélicobacters, Place Amélie Raba Léon, Bordeaux, Cedex 33076, France. philippe.lehours@u-bordeaux.fr.ORCID http://orcid.org/0000-0001-6077-1825

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aliarcobacter spp. bacteria are human enteropathogens, as are Campylobacter spp. However, the epidemiology of the former infections is not well described. Here, we present microbiological and clinical data on 1,204 Aliarcobacter spp. infections that occurred in France between 2002 and 2024. Aliarcobacter butzleri was the principal species identified, followed by A. cryaerophilus. Aliarcobacter spp. infections affected patients principally over 60 years of age, mostly men, particularly during autumn. Analysis of 253 clinical information sheets highlighted both diarrhea and abdominal pain that were only rarely associated with fever or blood in the stool. Many isolates of both main species were resistant to group A penicillins and ciprofloxacin.

Identifiers

PMID41422301
PMCPMC12781572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.